BioCorRx Inc. (OTC: BICX), a developer of innovative treatment support programs for substance abuse disorders, announced the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026. The report highlights key milestones achieved across commercial, clinical, intellectual property, and governance domains during 2026.
In preparation for a year-end commercial transition, BioCorRx Pharmaceuticals Inc., the company’s pharmaceutical subsidiary, established new National Drug Codes (NDCs) under its Labeler Code 85789. These new NDCs cover all four branded LUCEMYRA® (lofexidine) and authorized generic SKUs, ensuring uninterrupted market supply as the subsidiary assumes full commercial responsibility for the portfolio.
On the clinical front, BioCorRx initiated a Phase 1 clinical study titled "Safety and Pharmacokinetics Study of BICX104 With or Without Bupropion Compared to Vivitrol" (ClinicalTrials.gov Identifier: NCT07269873). This study evaluates BICX104, an investigational biodegradable naltrexone implant designed to provide sustained release of naltrexone for opioid use disorder (OUD) and alcohol use disorder treatment. The trial is conducted under the FDA’s 505(b)(2) regulatory pathway with support from the National Institute on Drug Abuse (NIDA).
Complementing its clinical advancements, BioCorRx secured U.S. Patent No. 12,569,430, which covers the biodegradable implant technology including naltrexone. This patent strengthens the company’s intellectual property portfolio protecting BICX104.
Governance enhancements were also notable, with Louis Lucido appointed as Chair of the Board of Directors. Additionally, former Acting White House Drug Policy Director Richard J. Baum joined BioCorRx’s Strategic Advisory Board, bringing valuable expertise to the company’s leadership team.
Lourdes Felix, Chief Executive Officer and Chief Financial Officer of BioCorRx Inc., commented, "2026 has been a transformative year of execution across both BioCorRx Inc. and our subsidiary, BioCorRx Pharmaceuticals Inc. By establishing our own NDCs ahead of the year-end commercial transition of LUCEMYRA® and its Authorized Generic, initiating our Phase 1 study for BICX104, expanding our patent protection, and strengthening our Board and advisory leadership, we are building real momentum heading into 2027."
BioCorRx offers addiction treatment solutions including the Beat Addiction Recovery program, which combines proprietary Cognitive Behavioral Therapy (CBT) modules, peer support via a mobile app, and medication prescribed by independent physicians. The company also operates the UnCraveRx® Weight Loss Program, a medication-assisted weight loss initiative supported by wellness specialists.
BioCorRx Pharmaceuticals Inc. focuses on pharmaceutical commercialization and development, including LUCEMYRA® (lofexidine), an FDA-approved oral medication indicated to mitigate opioid withdrawal symptoms in adults. LUCEMYRA® acts as a central alpha 2-adrenergic agonist to reduce norepinephrine release, thereby suppressing the neurochemical surge associated with opioid withdrawal. It is administered orally for up to 14 days with symptom-guided dosing and gradual discontinuation.
The company emphasizes that LUCEMYRA® is not a treatment for opioid use disorder itself and carries risks such as low blood pressure, slow heart rate, and fainting. Patients are advised to monitor for symptoms and consult healthcare providers accordingly.
BICX104, the investigational implant, is engineered to address adherence challenges associated with daily oral and monthly injectable naltrexone therapies by providing continuous, controlled drug release. Naltrexone is a non-addictive opioid receptor antagonist approved by the FDA for OUD and alcohol dependence but limited by real-world adherence issues.
The ongoing Phase 1 study of BICX104 is supported by NIDA under NIH Award Number U01DA059994. Prior research on the implant technology also received partial support from NIDA.
The report also highlights the growing public health concern of methamphetamine use disorder (MUD). According to the 2025 National Survey on Drug Use and Health (NSDUH), approximately 2.7 million Americans aged 12 or older reported methamphetamine use in the past year, with 1.8 million meeting criteria for MUD. There are currently no FDA-approved medications for MUD, underscoring an unmet medical need.
BioCorRx continues to advance its pipeline and commercial operations to address substance use disorders through innovative therapies and comprehensive treatment programs. For more information, visit www.BioCorRx.com.
BioCorRx Reports Q3 2026 Form 10-Q Filing, Advances Clinical Trials and Secures New Patent for Naltrexone Implant BioCorRx Inc. has filed its Q3 2026 Form 10-Q, detailing significant progress in commercial, clinical, intellectual property, and governance areas. The company established new National Drug Codes for LUCEMYRA® and its a... Read the full IIPLA article: https://iipla.org/news/biocorrx-reports-q3-2026-form-10-q-filing-advances-clinical-trials-and-secures-new-patent-for-naltrexone-implant